Last reviewed · How we verify

Daivonex® scalp solution

LEO Pharma · FDA-approved active Small molecule

Daivonex scalp solution is a vitamin D3 analogue that binds to vitamin D receptors on skin cells to reduce excessive cell proliferation and inflammation characteristic of psoriasis.

Daivonex scalp solution is a vitamin D3 analogue that binds to vitamin D receptors on skin cells to reduce excessive cell proliferation and inflammation characteristic of psoriasis. Used for Psoriasis of the scalp.

At a glance

Generic nameDaivonex® scalp solution
SponsorLEO Pharma
Drug classVitamin D3 analogue
TargetVitamin D receptor (VDR)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Calcipotriol (the active ingredient) is a synthetic analogue of calcitriol (active vitamin D3) that modulates keratinocyte differentiation and proliferation by activating vitamin D receptors. This leads to normalization of the abnormal skin cell growth cycle seen in psoriasis and reduces inflammatory cytokine production, thereby improving scaling, erythema, and plaque formation on the scalp.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results